Table 2.
Patients’ Characteristics in the MDACC Validation Sets
| MDACC: RD (n=113) | Metastasis (n=55) | Non-Metastasis (n=58) | |
|---|---|---|---|
| Age, years (median(range)) | 50 (28, 75) | 51 (28, 72) | 49 (32, 75) |
| Clinical T stage | |||
| T1 | 5 (4.4%) | 2 (1.7%) | 3 (2.7%) |
| T2 | 47 (41.6%) | 16 (14.2%) | 31 (27.4%) |
| T3 | 38 (33.6%) | 20 (17.7%) | 18 (15.9%) |
| T4 | 23 (20.4%) | 17 (15.0%) | 6 (5.4%) |
| Clinical N stage | |||
| N0 | 26 (23.0%) | 9 (8.0%) | 17 (15.0%) |
| N+ | 87 (77.0%) | 46 (40.7%) | 41 (36.3%) |
| RCB (residual cancer burden) | |||
| 0/I | 13 (11.5%) | 2 (1.7%) | 11 (9.8%) |
| II | 46 (40.7%) | 13 (11.5%) | 33 (29.2%) |
| III | 40 (35.4%) | 32 (28.4%) | 8 (7.0%) |
| NA | 14 (12.4%) | 8 (7.0%) | 6 (5.4%) |
| Samples | |||
| Biopsy | 113 (100%) | 55 (48.7%) | 58 (51.3%) |
| NACT | |||
| Sequential taxane and anthracycline | 113 (100%) | 55 (48.7%) | 58 (51.3%) |
| Follow-up (years, median, range) | 1.86 (0.09, 7.44) | 0.99 (0.09, 5.59) | 2.68 (0.90, 7.44) |
| C-Index | 0.62 | / | / |
Abbreviation: NACT, neoadjuvant chemotherapy.